In short
Clinical trials are investigating VERCIRNON in a small phase 1 study. The trial looks at how a PET radiotracer behaves in the body after VERCIRNON is given to healthy participants, with a focus on Crohn's disease-related targets. The study aims to measure where the tracer goes and how strongly it binds in the abdomen.
Key points
- Clinical trials of VERCIRNON in the provided data focus on a small Phase 1 PET study. The study involved healthy participants and was linked to Crohn's disease research. Researchers examined where the radiotracer [11C]AZ14132516 went in the body after VERCIRNON was given. They also measured tracer uptake and binding in abdominal regions of interest. The trial was completed and enrolled 9 people.
Trial overview
This article covers one clinical trial of VERCIRNON, identified as 2022-502843-36-00, which was a completed Phase 1 interventional study. The study used a PET scan approach to examine where the radiotracer [11C]AZ14132516 goes in the body after VERCIRNON was given.
Who participated
The trial enrolled 9 healthy participants. Even though the participants were healthy, the study was linked to Crohn's disease research because the condition was listed in the trial data.
What was measured
The main results were standard uptake value (SUV) and standard uptake value ratio (SUVR) in regions of interest. These scan measures help show how much tracer is taken up and how much total binding occurs to CCR9 in the body areas being studied.
The brief summary says the study aimed to examine the distribution of [11C]AZ14132516 and its binding to CCR9 in anatomical regions of interest in the abdominal area. In simple words, researchers wanted to see where the tracer traveled and how it behaved in the belly area on the scan.
Study design and phase
This was an interventional study, which means researchers gave the study intervention and then observed the results. It was in Phase 1, the earliest stage of clinical research, which is often used to gather first information about how a study test performs in people.
Condition focus: Crohn's disease
The only condition named in the source data was Crohn's disease. The trial did not describe treatment of symptoms; instead, it focused on imaging and binding measurements that may help researchers study this condition in the abdominal area.